Advanced

Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia

Olsson, Bob; Hertze, Joakim LU ; Ohlsson, Mattias LU ; Nägga, Katarina LU ; Hoglund, Kina; Basun, Hans; Annas, Peter; Lannfelt, Lars; Andreasen, Niels and Minthon, Lennart LU , et al. (2013) In Journal of Alzheimer's Disease 34(3). p.673-679
Abstract
Heart fatty acid binding protein (HFABP) is expressed in the brain and is elevated in cerebrospinal fluid (CSF) from patients with several forms of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease with dementia, Lewy body dementia, vascular dementia (VaD), and Creutzfeldt-Jakob disease. However, whether HFABP in CSF is a stable biomarker or if it can help predict conversion from mild cognitive impairment (MCI) to AD or VaD has not been well studied. To address the role of HFABP in neurodegeneration, we analyzed CSF levels of HFABP in 96 AD patients and 65 controls and also in 170 patients with MCI with an average follow up time of 5.7 years. For the stability analysis, two CSF samples were collected from 52... (More)
Heart fatty acid binding protein (HFABP) is expressed in the brain and is elevated in cerebrospinal fluid (CSF) from patients with several forms of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease with dementia, Lewy body dementia, vascular dementia (VaD), and Creutzfeldt-Jakob disease. However, whether HFABP in CSF is a stable biomarker or if it can help predict conversion from mild cognitive impairment (MCI) to AD or VaD has not been well studied. To address the role of HFABP in neurodegeneration, we analyzed CSF levels of HFABP in 96 AD patients and 65 controls and also in 170 patients with MCI with an average follow up time of 5.7 years. For the stability analysis, two CSF samples were collected from 52 AD patients with a six month interval in between. HFABP levels in CSF were very stable over the six month period (r = 0.93, p < 0.001). Furthermore, the CSF levels of HFABP were significantly elevated in AD compared with controls after adjustments for age and gender (p < 0.001). They were also elevated in the patients with MCI that subsequently converted to AD or VaD compared with those that remained stable (p < 0.001 and p < 0.05, respectively). However, ROC curve analysis showed that HFABP had lesser predictive value in determining conversion from MCI to AD and VaD than A beta(42), t-tau, and p-tau. In conclusion, HFABP seems to be a stable CSF biomarker that reflects neuronal cell death in several neurodegenerative disorders, including early stages of AD and VaD. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, biomarker, cerebrospinal fluid, dementia, HFABP, vascular dementia
in
Journal of Alzheimer's Disease
volume
34
issue
3
pages
673 - 679
publisher
IOS Press
external identifiers
  • wos:000315991500011
  • scopus:84876364097
ISSN
1387-2877
DOI
10.3233/JAD-121384
language
English
LU publication?
yes
id
0dd61fed-83e8-4094-99ac-736fd5562294 (old id 3658167)
date added to LUP
2013-05-02 08:59:19
date last changed
2019-06-25 01:25:21
@article{0dd61fed-83e8-4094-99ac-736fd5562294,
  abstract     = {Heart fatty acid binding protein (HFABP) is expressed in the brain and is elevated in cerebrospinal fluid (CSF) from patients with several forms of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease with dementia, Lewy body dementia, vascular dementia (VaD), and Creutzfeldt-Jakob disease. However, whether HFABP in CSF is a stable biomarker or if it can help predict conversion from mild cognitive impairment (MCI) to AD or VaD has not been well studied. To address the role of HFABP in neurodegeneration, we analyzed CSF levels of HFABP in 96 AD patients and 65 controls and also in 170 patients with MCI with an average follow up time of 5.7 years. For the stability analysis, two CSF samples were collected from 52 AD patients with a six month interval in between. HFABP levels in CSF were very stable over the six month period (r = 0.93, p &lt; 0.001). Furthermore, the CSF levels of HFABP were significantly elevated in AD compared with controls after adjustments for age and gender (p &lt; 0.001). They were also elevated in the patients with MCI that subsequently converted to AD or VaD compared with those that remained stable (p &lt; 0.001 and p &lt; 0.05, respectively). However, ROC curve analysis showed that HFABP had lesser predictive value in determining conversion from MCI to AD and VaD than A beta(42), t-tau, and p-tau. In conclusion, HFABP seems to be a stable CSF biomarker that reflects neuronal cell death in several neurodegenerative disorders, including early stages of AD and VaD.},
  author       = {Olsson, Bob and Hertze, Joakim and Ohlsson, Mattias and Nägga, Katarina and Hoglund, Kina and Basun, Hans and Annas, Peter and Lannfelt, Lars and Andreasen, Niels and Minthon, Lennart and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar},
  issn         = {1387-2877},
  keyword      = {Alzheimer's disease,biomarker,cerebrospinal fluid,dementia,HFABP,vascular dementia},
  language     = {eng},
  number       = {3},
  pages        = {673--679},
  publisher    = {IOS Press},
  series       = {Journal of Alzheimer's Disease},
  title        = {Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia},
  url          = {http://dx.doi.org/10.3233/JAD-121384},
  volume       = {34},
  year         = {2013},
}